CLAIMS

1. A compound of general formula (I)



(I)

any of its stereoisomers or any mixture of its stereoisomers or a pharmaceutically acceptable salt thereof,
wherein R is branched butyl.

2. The compound according to claim 1, any of its stereoisomers or any mixture of its stereoisomers or a pharmaceutically acceptable salt thereof, wherein R is 1-methylpropyl, 2-methylpropyl, or *tert*-butyl.

3. The compound according to claim 1, which is [(1S)-1-methylpropyl] 1-[8-methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo-[1,5-a]pyridin-2-yl]cyclopropanecarboxylate, free base.

4. The compound according to claim 1, which is [(1R)-1-Methylpropyl] 1-[8-methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate, free base.

5. The compound according to claim 1, which is [2-Methylpropyl] 1-[8-methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate, free base.

6. The compound according to claim 1, which is *Tert*-butyl 1-[8-methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate, free base.

7. A pharmaceutical composition comprising a compound according to any one of claims 1-6 together with a pharmaceutically acceptable vehicle or excipient or pharmaceutically acceptable carrier(s).

8. The pharmaceutical composition according to claim 7 further comprising one or more other therapeutically active compound(s).

9. A use of the compound according to any of the claims 1-6, for the manufacture of a pharmaceutical composition.

10. The use of a compound according to claim 9 in the manufacture of a pharmaceutical composition for the treatment or amelioration of a disease, disorder or condition responsive to PDE4 inhibitory activity.

11. The use according to claim 10, wherein the disease, disorder or condition is dermal diseases or conditions.

12. The use according to claim 11, wherein the disease, disorder or condition is proliferative and inflammatory skin disorders, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, psoriasis, cancer, epidermal inflammation, alopecia, skin atrophy, steroid induced skin atrophy, skin ageing, photo skin ageing, acne, urticaria, pruritis, and eczema.

13. The compound according to any of the claims 1-6, for use as a medicament.

14. The compound according to claim 13 for use in the treatment or amelioration of a disease, disorder or condition responsive to PDE4 inhibitory activity.

15. The compound according to claim 13 for use in the treatment or amelioration of dermal diseases or conditions.

16. The compound according to claim 13 for use in the treatment of proliferative and inflammatory skin disorders, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, psoriasis, cancer, epidermal inflammation, alopecia, skin atrophy, steroid induced skin atrophy, skin ageing, photo skin ageing, acne, urticaria, pruritis, and eczema.

17. A method for treatment or alleviation of a disease or a disorder or a condition responsive to PDE4 inhibitory activity, which method comprises the step of administering to a living animal body a therapeutically effective amount of a compound according to any of the claims 1-6.

18. A method of treating or ameliorating dermal diseases or conditions, the method comprising administering to a person suffering from at least one of said diseases an effective amount of one or more compounds according to according to any one of claims 1-6, optionally together with a pharmaceutically acceptable carrier or one or more excipients, optionally in combination with other therapeutically active compounds.

19. The method according to claim 18, wherein the dermal disease or condition is selected from the group consisting of proliferative and inflammatory skin disorders, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, psoriasis, cancer, epidermal inflammation, alopecia, skin atrophy, steroid induced skin atrophy, skin ageing, photo skin ageing, acne, urticaria, pruritis, and eczema.

Claims

1. A compound of general formula (I)



(I)

any of its stereoisomers or any mixture of its stereoisomers or a pharmaceutically acceptable salt thereof, wherein R is branched butyl.

2. The compound according to claim 1, any of its stereoisomers or any mixture of its stereoisomers or a pharmaceutically acceptable salt thereof, wherein R is 1-methylpropyl, 2-methylpropyl, or tert-butyl.

3. The compound according to claim 1, which is
[(1S)-1-methylpropyl] 1-[8-methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo-[1,5-a]pyridin-2-yl]cyclopropanecarboxylate, free base.

4. The compound according to claim 1, which is
[(1R)-1-Methylpropyl] 1-[8-methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate, free base.

5. The compound according to claim 1, which is
[2-Methylpropyl] 1-[8-methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate, free base.

6. The compound according to claim 1, which is
Tert-butyl 1-[8-methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate, free base.

7. A pharmaceutical composition comprising a compound according to any one of claims 1-6 together with a pharmaceutically acceptable vehicle or excipient or pharmaceutically acceptable carrier(s).

8. The pharmaceutical composition according to claim 7 further comprising one or more other therapeutically active compound(s).

9. The use of the compound according to any of the claims 1-6, in the manufacture of a pharmaceutical composition for the treatment or amelioration of a disease, disorder or condition responsive to PDE4 inhibitory activity; wherein the disease, disorder or condition is proliferative and inflammatory skin disorders, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, psoriasis, cancer, epidermal inflammation, alopecia, skin atrophy, steroid induced skin atrophy, skin ageing, photo skin ageing, acne, urticaria, pruritis, and eczema.

10. The compound according to any of the claims 1-6, for use as a medicament.

11. The compound according to claim 10 for use in the treatment or amelioration of a disease, disorder or condition responsive to PDE4 inhibitory activity.

12. The compound according to claim 10 for use in the treatment or amelioration of dermal diseases or conditions.

13. The compound according to claim 10 for use in the treatment of proliferative and inflammatory skin disorders, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, psoriasis, cancer, epidermal inflammation, alopecia, skin atrophy, steroid induced skin atrophy, skin ageing, photo skin ageing, acne, urticaria, pruritis, and eczema.